Hypertension pharmacogenomics

Gong, Y., McDonough, C. W., Padmanabhan, S. and Johnson, J. A. (2014) Hypertension pharmacogenomics. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Academic Press: London, pp. 747-778. ISBN 9780123868831 (doi: 10.1016/B978-0-12-386882-4.00032-3)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/B978-0-12-386882-4.00032-3


Hypertension is the most important modifiable risk factor for cardiovascular disease. Despite the plethora of effective pharmacological treatment options, data across the globe suggest that blood pressure control rates are less than 50%. This is likely influenced by the inability to predict which antihypertensive drug an individual is likely to respond to. Hypertension pharmacogenomics has the potential to identify genetic biomarkers for antihypertensive drug response and prediction of adverse cardiovascular outcomes, which might be used in the future in treatment selection. Research in the field (especially though genome-wide association studies) is also likely to enhance our understanding of hypertension and the mechanisms by which the various drugs produce efficacy. There are several examples of genes with compelling evidence on associations of genetic polymorphisms with antihypertensive response. The International Consortium for Antihypertensives Pharmacogenomics Studies will facilitate collaboration between research groups and translating the findings into clinical implementation.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Padmanabhan, Professor Sandosh
Authors: Gong, Y., McDonough, C. W., Padmanabhan, S., and Johnson, J. A.
Subjects:R Medicine > RM Therapeutics. Pharmacology
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Publisher:Academic Press
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record